We mourn the passing of Jose M. Parracho, one of the Exon 20 Group members who had the longest progression-free survival on amivantamab.
Jose was the quintessential model patient--so sweet, wanting to do everything right, and his world class oncology teams loved him.
The Exon 20 Group, as we do with many patient cases, learned a great deal from what Jose experienced throughout. Those insights have been helping and will continue to assist other exon 20 insertion patients as well.
On behalf of everyone at the Exon 20 Group, we send our deepest sympathies to the Parracho and Inacio families on Jose's passing.
Robert T. Hanlon, PhD
Marcia K. Horn, JD
Kristen Leniz
and the Exon 20 Council
About | About the Jose M. Parracho Advocacy Program |
Photos | Jose, family and friends photos |
Inspiration | Inspiration Jose lived by |
Memories | Family and friends share their memories |
Literature | Literature, news and videos pertinent to the |
The Jose M. Parracho Advocacy Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Advocacy Programs.
For more information, please email Jose.ParrachoProgram@askican.org
To support this program, please click below.
We also accept PayPal
paypal.me/ICANadvocacy
About ICAN
Mission
ICAN's mission is to assist and empower late-stage patients worldwide with cutting-edge information regarding anticancer drugs in clinical trials as well as physician referrals at the patient’s request based on the patient’s reported medical situation. ICAN takes the position that there are key decision points in the battle for life and with the best available information, the cancer patient will be well-armed for the road ahead.